Ninjacart Startup Program Launches to Empower FoodTech and AgTech Startups in Accelerating Growth
9.12.2024 11:00:00 CET | Business Wire | Press release
Ninjacart, India’s leading agri-tech startup has announced the launch of its Ninjacart Startup Program. This agri-tech-focused startup program aims to accelerate the growth of early-stage FoodTech and AgTech startups by providing access to cutting-edge technology, venture capital partners, financial backing, and expert business advisory.
With nearly a decade of experience in transforming agricultural ecosystems, Ninjacart has collaborated with global agri-tech innovators to optimize supply chains and address distribution challenges. The Ninjacart Startup Program leverages this expertise to help startups scale faster, drive change, and lead the future of food distribution.
The Ninjacart Startup Program offers four key benefits to participants:
- Access to Ninjacart’s Advanced Technology: Ninjacart’s industry-leading, cutting edge technology offers startups access to a focused suite of supply chain management proprietary tools to drive growth or enhance operational efficiency. Growth tools include demand forecasting, sales management, pricing intelligence, campaign management, and customer app. Operational tools include procurement, inventory management, workforce management, logistics, and catalog management.
- Pitch to VC Partners: Startups will have the chance to present to top VC partners such as Syngenta Group Ventures and Base Capital on Demo Day, scheduled for February 2025.
- Financial Backing: Ninjacart offers credits up to $50,000 to offset platform and implementation fees during the first six months of participation.
- Expert Business Advisory: Participants will gain access to Ninjacart’s domain expertise in building scalable supply chains for fresh produce, meat, and staples, offering tailored guidance to shorten their path to profitability.
The program is open to emerging startups founded in 2020 or later, with up to $1 million in funding, operating outside India. Eligible startups must be post-revenue and focused on innovating the food supply chain.
“At Ninjacart, we’ve always believed in the transformative power of technology to solve critical supply chain inefficiencies,” said Kartheeswaran KK, Co-Founder and CEO, Ninjacart. “The Ninjacart Startup Program is designed to empower innovators who are driving systemic change in food systems. By offering our expertise, technology, and network, we aim to help startups accelerate their startup journey and propel the collective transformation of the global agriculture ecosystem.”
Applications for the inaugural cohort of the Ninjacart Startup Program are now open. Startups eager to scale and transform food systems can visit https://ninjacart.com/ninjacart-startup-program/ or contact nsp@ninjacart.comto apply.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241207248527/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom